Friday - April 03, 2026

Category Archives: Pharmaceuticals & Biotech

Oligonucleotide Synthesis Market Projected to Reach $24.7 Billion by 2030 Driven by Expanding Genomics Applications

Oligonucleotide Synthesis Market by Product ((Drugs (ASO, siRNA), Synthesized Oligos (Product (Primers, Probes)), Type ((Custom, Predesigned), Reagents, Equipment), Application (Therapeutic (Rare Diseases), Research, Diagnostics) – Global Forecast to 2030 According to MarketsandMarkets™, the global Oligonucleotide Synthesis Market is poised for … Continue reading →

POLYKEM Strategic Procurement Guide: Why Global B2B Buyers are Prioritizing POLYKEM Synthetic Rubber and Specialty Chemical Surfactants in 2026

Qingdao Polykem Co., Ltd. Qingdao Polykem Co., Ltd. (POLYKEM) is a premier R&D-driven manufacturer with 15+ years of expertise in high-performance Synthetic Rubber and specialty chemicals. Serving 700+ clients across 100+ industries, POLYKEM provides 115+ products, including PEG, HNBR, and … Continue reading →

Obesity Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Merck, Alizyme, Bayer, GlaxoSmithKline, Bristol-Myers Squibb, Currax Pharma, Roche

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Obesity pipeline constitutes 80+ key companies continuously working towards developing 100+ Obesity treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.   … Continue reading →

Metastatic Prostate Cancer Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Curium, Merck/ Orion, Pfizer, AstraZeneca, Telix Pharma, Tavanta

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Metastatic Prostate Cancer pipeline constitutes 80+ key companies continuously working towards developing 85+ Metastatic Prostate Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and … Continue reading →

Open Angle Glaucoma Market: Expanding Revenue Landscape to 2034 – DelveInsight | Visiox Pharma, TearClear, VivaVision Biotech, Abbvie, Ocuphire Pharma, Qlaris Bio, Nicox Ophthalmics, Sun Pharma

The Key Open Angle Glaucoma Companies in the market include – Ocuvex Therapeutics, Thea Pharma, Omikron Italia, PolyActiva Pty, OPIS Spain, D. Western Therapeutics Institute (DWTI), Ocular Therapeutix, Inc., MediPrint Ophthalmics, Tarsier Pharma, Peregrine Ophthalmic, Ocuphire Pharma, Qlaris Bio, Inc., … Continue reading →

Non Muscle Invasive Bladder Cancer Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics, Incyte Corp

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Non Muscle Invasive Bladder Cancer pipeline constitutes 20+ key companies continuously working towards developing 22+ Non Muscle Invasive Bladder Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, … Continue reading →

Multiple System Atrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Brain Neuro

The Key Multiple System Atrophy Companies in the market include – Teva Pharmaceutical/MODAG GmBH, H. Lundbeck A/S/Genmab, Alterity Therapeutics, Theravance Biopharma, Ionis Pharmaceuticals, Inc., Biohaven Pharmaceuticals, Lundbeck A/S, Alterity Therapeutics, Brain Neurotherapy Bio, Inc., Biogen, Corestem, Inc., Modag, AC Immune, … Continue reading →

Motor Neuron Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 180+ Key Companies | DelveInsight

DelveInsight’s, “Motor Neuron Disease Pipeline Insight 2026” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Motor Neuron Disease pipeline landscape. It covers the Motor Neuron Disease pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading →